Trevi Therapeutics, Inc.
TRVI
$7.55
$0.060.80%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -18.97% | 9.42% | 13.80% | -7.21% | -13.30% |
| Total Depreciation and Amortization | 2.70% | -2.63% | 5.56% | -5.26% | 8.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 20.11% | 13.08% | 64.59% | -45.02% | 95.67% |
| Change in Net Operating Assets | 125.64% | -506.24% | -68.00% | 15.62% | 4,498.39% |
| Cash from Operations | 25.05% | -41.12% | 0.06% | -10.05% | 17.04% |
| Capital Expenditure | -- | -- | -- | 100.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 73.77% | 58.30% | -411.27% | 174.21% | 134.56% |
| Cash from Investing | 73.77% | 58.32% | -411.36% | 176.99% | 134.21% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 64.52% | 3.13% | -3.23% | 3.13% |
| Issuance of Common Stock | 1,139.24% | -82.64% | 927.90% | -1.73% | 127,350.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -65.77% | -- | -- | -- | -- |
| Cash from Financing | 1,168.18% | -83.09% | 933.89% | -1.76% | 18,196.43% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 763.48% | -181.59% | 484.17% | 464.27% | 95.44% |